CRDF – cardiff oncology, inc. (US:NASDAQ)
Stock Stats
News
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC [Yahoo! Finance]
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development [Yahoo! Finance]
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
Form SC 13G Cardiff Oncology, Inc. Filed by: BlackRock, Inc.
Form 8-K Cardiff Oncology, Inc. For: Nov 07
Form 10-Q Cardiff Oncology, Inc. For: Sep 30
Form SC 13G Cardiff Oncology, Inc. Filed by: BlackRock, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.